Bexarotene/betamethasone dipropionate

Drug Profile

Bexarotene/betamethasone dipropionate

Alternative Names: Betamethasone dipropionate/bexarotene; LAS 41004

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Almirall S.A.
  • Class Anti-inflammatories; Antipsoriatics; Benzoic acids; Fluorinated steroids; Glucocorticoids; Naphthalenes; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoid X receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Plaque psoriasis

Most Recent Events

  • 13 Oct 2014 Almirall completes a phase IIa trial in Plaque psoriasis in Germany (EudraCT2013-003757-22)
  • 21 Aug 2014 Almirall completes a phase I/II trial in Plaque psoriasis in Germany (NCT02111499)
  • 05 May 2014 Almirall initiates enrolment in a phase IIa trial for Plaque psoriasis in Germany (EudraCT2013-003757-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top